Drug intelligence / Profile preview

EBP-F.prau-LBP1

Development stage: Unknown
Lead developer: Enterobiome
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

EBP-F.prau-LBP1 is a live biotherapeutic product (LBP) developed by Enterobiome, utilizing the keystone gut commensal bacterium *Faecalibacterium prausnitzii*. It is designed to address hair and skin conditions through the modulation of the gut-skin axis. *F. prausnitzii* is recognized for its significant anti-inflammatory properties, primarily mediated through the production of butyrate and other metabolites that support intestinal barrier integrity and systemic immune homeostasis. The product is currently in Phase 1 clinical development, targeting therapeutic applications where microbiome dysbiosis contributes to dermatological and hair health issues.

Other names: Enterobiome-F.prausnitzii-LBP (hair/skin)

Beyond the preview

Go deeper on EBP-F.prau-LBP1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EBP-F.prau-LBP1.

Explore the full profile